Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Bexmarilimab

Generic Name: Bexmarilimab

Drug Type: Biotech

CAS Number: 2259301-27-2

Unique Ingredient Identifier: SA0O2AK3LA

Overview

Bexmarilimab is under investigation in clinical trial NCT03733990 (A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients).

Background

Bexmarilimab is under investigation in clinical trial NCT03733990 (A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Phase 1

Recruiting

Posted: 2022/06/23

Sponsor:

Faron Pharmaceutical...

ID:NCT05428969

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Phase 1

Withdrawn

Posted: 2021/12/28

Sponsor:The University of Te...

ID:NCT05171062

A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma

Phase 1

Withdrawn

Posted: 2021/11/03

Sponsor:

Faron Pharmaceutical...

ID:NCT05104905

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Faron Pharmaceuticals Appoints Ralph Hughes as Chief Business Officer to Advance Immunotherapy Pipeline

4 days ago

Faron Pharmaceuticals has appointed Ralph Hughes as Chief Business Officer, bringing extensive experience in commercial strategy and market access from his previous roles at PharmaVentures, Mundipharma, and Pfizer.

Finnish Researchers Develop Gene Signature Test to Predict Cancer Immunotherapy Response

5 days ago

University of Turku scientists have identified a five-gene signature that predicts which cancer patients will respond to bexmarilimab immunotherapy, potentially improving treatment outcomes through personalized selection.

Orca Bio's Phase III Precision-T Study Shows Promise for Novel T-Cell Immunotherapy in Blood Cancers

2 months ago

Orca Bio announced positive results from its pivotal Phase III Precision-T study evaluating Orca-T, an investigational allogeneic T-cell immunotherapy for various blood cancers including AML, ALL, and high-risk MDS.

Global Clinical Trials for Myelodysplastic Syndrome Show Significant Industry Investment in 2025

3 months ago

A comprehensive review of global Myelodysplastic Syndrome clinical trials reveals extensive research activity across G7 and E7 countries, with major pharmaceutical companies leading development efforts.

FDA Grants Orphan Drug Designation to Bexmarilimab for Myelodysplastic Syndrome Treatment

3 months ago

Faron Pharmaceuticals' lead candidate bexmarilimab receives FDA Orphan Drug Designation for myelodysplastic syndromes treatment, offering development incentives and seven-year marketing exclusivity upon approval.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy